Clinical Trials: A clinical trial involves research participants. It follows a pre-defined plan or protocol to evaluate the effects of a medical or behavioral intervention on health outcomes. Clinical trials are done to determine whether new drugs or treatments are safe and effective. By taking part in clinical trials, participants not only play a more active role in their own health care, but they also can access experimental treatments and help others by contributing to medical research.
Cancer immunotherapy has demonstrated promising results. However, to date, researchers have failed to overcome the complex interplay between the immune system and the immune suppressive tumor...
As one of the nation's most prevalent sexually transmitted infections, genital herpes represents a diagnostic and therapeutic challenge to clinicians, laboratorians and the patients they...
As hospitals and healthcare systems move toward value-based care, new management systems are needed to measure and improve clinical processes. This presents both an opportunity and a ch...
Medical Technology Partner’s presentation is designed highlight what Medicare is proposing to do based on the Protecting Access to Medicare Act of April 1, 2014 with regard to clinical...
This lecture will provide attendees with the knowledge and skills to bring on new clinical laboratory tests in clinical chemistry and molecular diagnostics. The lecture will provide a general...
Diagnosis and management of CKD requires a spectrum of diagnostic tests to not only diagnose kidney function but also determine the status of other complications due to CKD, including creatin...
DNASTAR offers an integrated suite of software for accurate assembly, alignment, and analysis of sequence data from all major next-generation sequencing platforms, supporting key workflows in...
In November of 2013 the AHA/ACA jointly proposed new guidelines for the management of hypercholesterolemia, the first full update in over a decade. The charge was to create evidence bas...
Aggressive low-density lipoprotein cholesterol (LDL-C) lowering strategies are recommended for prevention of cardiovascular events in high-risk populations. Guidelines recommend a 30-50% redu...
Until recently most of the phenotypic information on congenital endocrine disorders have relied on biochemical testing of steroids, biogenic amines and peptides but is now...
Liquid chromatography triple quadrupole mass spectrometry (LC/MS/MS) is ideally suited for the direct and rapid analysis of prepared biological samples. While analysis times can be shortened...
FDA has generally not enforced applicable regulatory requirements on a group of IVD tests called Laboratory Developed Tests. This use of “enforcement discretion” has been un...
There is agreement among clinicians that laboratory analyses are indispensable for correct diagnosis of disease, therapy, and patient monitoring. It is evident that laboratory data should be...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Next-generation sequencing has emerged as a valuable tool for generating patient-specific genetic information for clinical diagnostics and optimal selection of targeted therapies. The heterog...
Drugs of abuse toxicology testing by immunoassays is widely used clinically, but also known to be inadequate for many clinical indications. In this presentation, the speaker will outline diff...
Stage IV melanoma carried a 24 month life expectancy three short years ago. That is what T.J. Sharpe’s first oncologist told him he was facing, after a visit to the ER for a fever turne...
The 95% failure rate of anticancer therapeutic being approved after positive Phase III trials suggests that existing pre-clinical approaches and tools are inadequate predictors of clinical ou...
Biomarkers, with their associated “tsunami” of publications, represent what is arguably one of the largest areas of scientific inquiry in the history of biomedicine. Touted as the...
The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians mi...
The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prio...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
DATE: Sept 22, 2015TIME: 9:00am PDT, 12:00PM EDTHeart failure is a complex syndrome and affects over 5.1 Million Americans today with approximately 500,000 new heart failure cases each year. ...
Learning Objectives for this presentation -
(1) Understand how human genetics can contribute to drug discovery and development.
(2) Understand the role of biomarkers and clinical proof-...
Cancer immunotherapy has demonstrated promising results. However, to date, researchers have failed to overcome the complex interplay between the immune system and the immune suppressive tumor...
As one of the nation's most prevalent sexually transmitted infections, genital herpes represents a diagnostic and therapeutic challenge to clinicians, laboratorians and the patients they...
As hospitals and healthcare systems move toward value-based care, new management systems are needed to measure and improve clinical processes. This presents both an opportunity and a ch...
Medical Technology Partner’s presentation is designed highlight what Medicare is proposing to do based on the Protecting Access to Medicare Act of April 1, 2014 with regard to clinical...
This lecture will provide attendees with the knowledge and skills to bring on new clinical laboratory tests in clinical chemistry and molecular diagnostics. The lecture will provide a general...
Diagnosis and management of CKD requires a spectrum of diagnostic tests to not only diagnose kidney function but also determine the status of other complications due to CKD, including creatin...
DNASTAR offers an integrated suite of software for accurate assembly, alignment, and analysis of sequence data from all major next-generation sequencing platforms, supporting key workflows in...
In November of 2013 the AHA/ACA jointly proposed new guidelines for the management of hypercholesterolemia, the first full update in over a decade. The charge was to create evidence bas...
Aggressive low-density lipoprotein cholesterol (LDL-C) lowering strategies are recommended for prevention of cardiovascular events in high-risk populations. Guidelines recommend a 30-50% redu...
Until recently most of the phenotypic information on congenital endocrine disorders have relied on biochemical testing of steroids, biogenic amines and peptides but is now...
Liquid chromatography triple quadrupole mass spectrometry (LC/MS/MS) is ideally suited for the direct and rapid analysis of prepared biological samples. While analysis times can be shortened...
FDA has generally not enforced applicable regulatory requirements on a group of IVD tests called Laboratory Developed Tests. This use of “enforcement discretion” has been un...
There is agreement among clinicians that laboratory analyses are indispensable for correct diagnosis of disease, therapy, and patient monitoring. It is evident that laboratory data should be...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Next-generation sequencing has emerged as a valuable tool for generating patient-specific genetic information for clinical diagnostics and optimal selection of targeted therapies. The heterog...
Drugs of abuse toxicology testing by immunoassays is widely used clinically, but also known to be inadequate for many clinical indications. In this presentation, the speaker will outline diff...
Stage IV melanoma carried a 24 month life expectancy three short years ago. That is what T.J. Sharpe’s first oncologist told him he was facing, after a visit to the ER for a fever turne...
The 95% failure rate of anticancer therapeutic being approved after positive Phase III trials suggests that existing pre-clinical approaches and tools are inadequate predictors of clinical ou...
Biomarkers, with their associated “tsunami” of publications, represent what is arguably one of the largest areas of scientific inquiry in the history of biomedicine. Touted as the...
The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians mi...
The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prio...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
DATE: Sept 22, 2015TIME: 9:00am PDT, 12:00PM EDTHeart failure is a complex syndrome and affects over 5.1 Million Americans today with approximately 500,000 new heart failure cases each year. ...
Learning Objectives for this presentation -
(1) Understand how human genetics can contribute to drug discovery and development.
(2) Understand the role of biomarkers and clinical proof-...
Follow
